Biphasic effects of ingenol 3,20-dibenzoate on the erythropoietin receptor: Synergism at low doses and antagonism at high doses

Molecular Pharmacology

Volumn 88, Issue 2, 2015, Pages 392-400

  Oh, Jin Gyo ^a   Chin, Young Won ^b   Kim, Sung Jo ^c   Choi, Jong Min ^d   Kim, Sang Kyum ^d   Kang, Hee Eun ^a   Heo, Tae Hwe ^a  

^a The Catholic University of Korea   (South Korea)

^b Dongguk University   (South Korea)

^c Hoseo University   (South Korea)

^d Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DITERPENE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; INGENOL DIBENZOATE; PROTEIN KINASE C;

ANEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CELL PROLIFERATION; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; HUMAN; METABOLISM; MUTATION; SIGNAL TRANSDUCTION;

ANEMIA; ANIMALS; CELL LINE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG SYNERGISM; ERYTHROPOIETIN; HUMANS; MICE, INBRED C57BL; MUTATION; PROTEIN KINASE C; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 84939840012     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.097436     Document Type: Article

References (38)

1. Asada A, Zhao Y, Kondo S, and Iwata M (1998) Induction of thymocyte apoptosis by Ca2+-independent protein kinase C (nPKC) activation and its regulation by calcineurin activation. J Biol Chem 273:28392-28398.
2. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, and McKoy JM, et al. (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-924.
3. Blanco-Molina M, Tron GC, Macho A, Lucena C, Calzado MA, Muñoz E, and Appendino G (2001) Ingenol esters induce apoptosis in Jurkat cells through an AP-1 and NF-kappaB independent pathway. Chem Biol 8:767-778.
4. Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, Rainger GE, Morris M, Lord JM, and Le TT, et al. (2006) Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 177:8123-8132.
5. Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, and Lodish HF (2001) Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci USA 98:4379-4384.
6. Driedger PE and Blumberg PM (1980) Specific binding of phorbol ester tumor promoters. Proc Natl Acad Sci USA 77:567-571.
7. Dunphy WG, Delclos KB, and Blumberg PM (1980) Characterization of specific binding of [3H]phorbol 12,13-dibutyrate and [3H]phorbol 12-myristate 13-acetate to mouse brain. Cancer Res 40:3635-3641.
8. Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, and Green JM, et al. (2006) Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 34:1303-1311.
9. Fujiwara M, Ijichi K, Tokuhisa K, Katsuura K, Shigeta S, Konno K, Wang GY, Uemura D, Yokota T, and Baba M (1996) Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate. Antimicrob Agents Chemother 40:271-273.
10. Goldberg J, Jin Q, Ambroise Y, Satoh S, Desharnais J, Capps K, and Boger DL (2002) Erythropoietin mimetics derived from solution phase combinatorial libraries. J Am Chem Soc 124:544-555.
11. Grue-Sørensen G, Liang X, Månsson K, Vedsø P, Dahl Sørensen M, Soor A, Stahlhut M, Bertelsen M, Engell KM, and Högberg T (2014) Synthesis, biological evaluation and SAR of 3-benzoates of ingenol for treatment of actinic keratosis and nonmelanoma skin cancer. Bioorg Med Chem Lett 24:54-60.
12. Hasler CM, Acs G, and Blumberg PM (1992) Specific binding to protein kinase C by ingenol and its induction of biological responses. Cancer Res 52:202-208.
13. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, and Dougherty C, et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260.
14. Hong KJ, Lee HS, Kim YS, and Kim SS (2011) Ingenol protects human T cells from HIV-1 infection. Osong Public Health Res Perspect 2:109-114.
15. Jørgensen L, McKerrall SJ, Kuttruff CA, Ungeheuer F, Felding J, and Baran PS (2013) 14-step synthesis of (+)-ingenol from (+)-3-carene. Science 341:878-882.
16. Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, and Blumberg PM (2004) Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 64:3243-3255.
17. Kessler C, Greindl A, Breuer B, Haberl U, Rybka A, Emgenbroich M, Frank HG, and Pötgens AJ (2012) Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities. Cytokine 57:226-237.
18. Kim SJ, Chin YW, and Heo TH (2013) Erythropoietic agents from natural sources. Altern Ther Health Med 19:54-60.
19. Komatsu N, Yamamoto M, Fujita H, Miwa A, Hatake K, Endo T, Okano H, Katsube T, Fukumaki Y, and Sassa S, et al. (1993) Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood 82:456-464.
20. Leyland-Jones B; BEST Investigators and Study Group (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459-460.
21. Liu Z, Stoll VS, Devries PJ, Jakob CG, Xie N, Simmer RL, Lacy SE, Egan DA, Harlan JE, and Lesniewski RR, et al. (2007) A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood 110:2408-2413.
22. McKerrall SJ, Jørgensen L, Kuttruff CA, Ungeheuer F, and Baran PS (2014) Development of a concise synthesis of (+)-ingenol. J Am Chem Soc 136:5799-5810.
23. Moyo V, Lefebvre P, Duh MS, Yektashenas B, and Mundle S (2008) Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 87:527-536.
24. Newton AC (1995) Protein kinase C: structure, function, and regulation. J Biol Chem 270:28495-28498.
25. Pérès EA, Valable S, Guillamo JS, Marteau L, Bernaudin JF, Roussel S, Lechapt-Zalcman E, Bernaudin M, and Petit E (2011) Targeting the erythropoietin receptor on glioma cells reduces tumour growth. Exp Cell Res 317:2321-2332.
26. Qureshi SA, Kim RM, Konteatis Z, Biazzo DE, Motamedi H, Rodrigues R, Boice JA, Calaycay JR, Bednarek MA, and Griffin P, et al. (1999) Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci USA 96:12156-12161.
27. Racke FK, Baird M, Barth RF, Huo T, Yang W, Gupta N, Weldon M, and Rutledge H (2012) Unique in vitro and in vivo thrombopoietic activities of ingenol 3,20 dibenzoate, a Ca(++)-independent protein kinase C isoform agonist. PLoS One 7:e51059.
28. Racke FK, Wang D, Zaidi Z, Kelley J, Visvader J, Soh JW, and Goldfarb AN (2001) A potential role for protein kinase C-epsilon in regulating megakaryocytic lineage commitment. J Biol Chem 276:522-528.
29. Sando JJ, Hilfiker ML, Salomon DS, and Farrar JJ (1981) Specific receptors for phorbol esters in lymphoid cell populations: role in enhanced production of T-cell growth factor. Proc Natl Acad Sci USA 78:1189-1193.
30. Shin SK, Ha SK, Lee KW, Yoo TH, Yun SR, Yoon SH, Kim SJ, Lee SK, and Heo TH (2010) Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera. J Pharm Biomed Anal 52:289-293.
31. Shin SK, Moon SJ, Ha SK, Jo YI, Lee TW, Lee YS, Kim YW, Kim DJ, Kim JK, and Yoo TH, et al. (2012) Immunogenicity of recombinant human erythropoietin in Korea: a two-year cross-sectional study. Biologicals 40:254-261.
32. Shoyab M and Todaro GJ (1980) Specific high affinity cell membrane receptors for biologically active phorbol and ingenol esters. Nature 288:451-455.
33. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, and Ogbourne SM (2010) PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol 51:99-105.
34. Szenajch J, Wcislo G, Jeong JY, Szczylik C, and Feldman L (2010) The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells from clinic to bench: a critical review. Biochim Biophys Acta 1806:82-95.
35. von Lindern M, Parren-van Amelsvoort M, van Dijk T, Deiner E, van den Akker E, van Emst-de Vries S, Willems P, Beug H, and Löwenberg B (2000) Protein kinase C alpha controls erythropoietin receptor signaling. J Biol Chem 275:34719-34727.
36. Wallvik J, Stenke L, Bernell P, Nordahl G, Hippe E, and Hast R (2002) Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol 68:180-185.
37. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, and Rudinskas L, et al. (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027-1032.
38. Wu P, Zhang N, Wang X, Zhang C, Li T, Ning X, and Gong K (2012) The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells. PLoS One 7:e45122.